Evaluated on SKEMPI v2.0 and SAbDab curated into three subsets: AbAgA (1,953 labeled affinity pairs), AbAgI (7,725 unlabeled interaction pairs), and AbAgKoff (272 kinetic pairs).
Compared against five PLM-based baseline setups, A2binder, AntiBERTa2, DG-Affinity, ESM-F, and AntiBERTY-F, which adapt pre-trained language models with regression heads for affinity tasks.
Generates pseudo-labels on 7,725 unlabeled pairs (AbAgI) using a teacher model trained on AbAgA; retraining on this expanded pool serves as the main engine for gains, boosting Pearson correlation from 0.45 to 0.68 and reducing MSE by ~35%.
Infuses explicit biological priors into sequence representations via an MEI module (sequence-based biophysical epitope features), CDR-masked attention (CAttention), and a Mixture-of-Experts (MoE) network to dynamically model diverse binding modes.
Extends beyond static equilibrium affinity (K_d) by using few-shot transfer learning on learned interaction features to predict dissociation rates (k_off) for target residence time analysis.
Results from the antibody discovery competition, where ML methods faced off with experimental baselines.
Participating organizations were evaluated across three tasks on a SARS-CoV-2 receptor-binding domain (RBD) dataset: (1) in silico affinity maturation by modifying non-HCDR3 CDRs using sequencing outputs, (2) affinity ranking of candidates within three HCDR3-clustered sequence datasets, and (3) out-of-library CDR optimization/design to generate novel high-affinity binders not present in the sequencing data.
For lead optimization, top ML methods matched experimental performance by producing sub-100 pM binders (top ML design: 95 pM vs. best experimental control: 113 pM), though overall ML submissions underperformed relative to experimental sorting libraries. Notably, a simple non-ML statistical consensus baseline also achieved a highly competitive 540 pM affinity without using machine learning.
For sequence ranking within HCDR3 clusters, almost all ML algorithms performed worse than random clone picking; only 9.8%-13.8% of ML submissions beat the cluster baseline clone compared to 39% from random selection. Additionally, out-of-library ML designs yielded a high proportion of non-binders (30.4%) and top-ranked affinity hits frequently suffered from severe biophysical developability failures.
ML is genuinely useful for timeline reduction during lead optimization and affinity maturation, replacing 2-3 weeks of physical combination library construction with an in silico step when provided with deep, biologically grounded experimental datasets.
Pretrained protein language models (PLMs) paired with structure-aware modules (e.g., pairformers) showed utility in exploring novel out-of-library sequence spaces. However, current ML models lack cross-task generalization, struggle with local epistasis, and fail to reliably co-optimize affinity alongside multiparametric biophysical developability.
Benchmarking the ability of co-folding models to distinguish nanobody binders and non-binders.
Evaluated four state-of-the-art structure prediction models (AlphaFold3, Boltz-2, Chai-1, and IntFold) across true binder ranking, out-of-distribution (OOD) sequence detection, and mutational sensitivity in nanobody–antigen complexes.
Discovered that no single confidence score excels across all tasks: while Boltz-2 achieved the highest median accuracy for true binder identification, local metrics like PLDDT (particularly in AlphaFold3) were far superior at catching OOD alanine-substituted sequences.
Contributed a original in vivo camelid immunization dataset targeting CD33, revealing that all evaluated models struggle to generalize when discriminating enriched binders from realistic immune repertoire background sequences.
Demonstrated that commonly used hard filtering thresholds (e.g., pAE < 10) can erroneously discard up to 75% of true binders, underscoring the need to combine complementary global interface and local CDR metrics rather than relying on single confidence scores.
Benchmark framework for universal antibody-antigen binding affinity prediction evaluated on the AlphaBind dataset.
Introduces MochiBind, a sequence-based pairwise predictor that compares two antibodies targeting the same antigen to determine which binds stronger.
Uses pretrained ESM-2 embeddings for antibody and antigen sequences, projecting pooled representations into an MLP to predict relative binding affinity.
Compared against structural proxies (Boltz-2, GeoDock) evaluated zero-shot without AlphaBind training, and Graphinity fine-tuned on AlphaBind.
Across the 4 AlphaBind target antigens, average pairwise accuracy reaches ~0.70 for MochiBind, ~0.65 for fine-tuned Graphinity, ~0.58 for Boltz-2, and ~0.50 (random performance) for GeoDock.
All training, fine-tuning, and out-of-sample evaluation in this study were conducted exclusively on the AlphaBind dataset.
The authors engineered a synthetic yeast-display Fab library centered on a compact "Antigen Recognition Module" (ARM), a <100 nt sequence pairing heavy-chain CDRH3 sequence diversity with a light-chain barcode, providing a computationally lightweight paratope representation tailored for high-throughput sequencing and ML workflows.
To overcome physical display biases (such as yeast growth rates or expression disparities), a k-mer-based logistic regression (LR) model was trained on sequence enrichment data from early sorting rounds (MACS to FACS1) to score clones based on sequence motifs.
Applying the LR model successfully rescued functional, high-affinity binders for ROBO2N (11 binders) and PD-L2 from early sequence pools that had been depleted or overshadowed by dominant clones in later experimental cell-sorting rounds.
The LR model trained on ROBO2N accurately predicted binding potency and epitope cluster preference for the closely related paralog ROBO1, while reliably scoring non-binding clones as low probability.
The paper provides a publicly available dataset of over 68,000 unique target-associated ARM sequences alongside comprehensive biophysical characterizations for 486 antibodies, offering a structured foundation for downstream predictive models, affinity maturation, and zero-shot antibody design.
Autoregressive model for sequence design, with applications to antibody-antigen design.
LOGOS was trained autoregressively on 44.87 billion scientific tokens across seven modalities, learning interaction constraints entirely from discrete sequences without natural language text or explicit 3D coordinate inputs (so UniRef, OAS, Smiles etc etc, not scientific ‘text’).
Cleaned antibody sequences from the Observed Antibody Space (OAS) were clustered at 70% sequence identity and encoded using a native scientific grammar with chain- and CDR-specific boundary tokens.
Evaluated on the SAbDab benchmark for antibody CDR design using Amino Acid Recovery (AAR), refolded structural self-consistency, and AntiBERTy sequence plausibility.
LOGOS-8B outperformed specialized 3D structure-conditioned inverse-folding baselines on conserved CDR1 and CDR2 loops, achieving over 85% AAR on CDR-L1 and CDR-L2 from sequence context alone - but if you train on OAS, this is hardly a surprise.
Novel structural co-folding method that rivals AF3 architectures whilst being completely open sourced.
OpenDDE replaces direct coordinate regression with atomic latent reasoning over granular structural tokens and scales the standard Pairformer hidden dimension from 128 to 384, expanding parameter capacity.
The model implements a differentiable shape-complementarity objective to physically fit interfaces and naturally unifies structure prediction and de novo design inside a single conditional diffusion framework via masking.
The model uses a 4-stage precision-breadth-precision data distribution to master geometry , consuming ~414k GPU-hours handled efficiently via Fold-CP context parallelism.
The model sets state-of-the-art antibody-antigen success rates (e.g., 70.0% on FoldBench-AB and 66.4% on 2026ARK-AB) , easily outperforming Protenix-v1 (beating/equalling AF3!), and climbs to nearly 90% oracle accuracy when scaled with test-time seeds.
Developability characterization of multispecific antibodies, for the purposes of training machine learning models
To map out developer behavior, the researchers used advanced diversity-sampling algorithms to select 160 unique bispecific combinations from 65 parental antibodies, capturing a vast spectrum of biophysical profiles.
Developability traits don’t transfer uniformly from parent to child; while hydrophobicity and charge are highly predictable, critical flaws like self-association often emerge unexpectedly as "outliers" when the two arms interact.
The study revealed that thermostability is strictly format-driven, meaning it cannot be reliably predicted from parental data and must be measured directly on the final multi-specific construct.
Very fast antibody modeling, FlashABB, with applications to developability screening.
FlashABB accurately performs sota antibody antibody structure prediction in just 5 ms, making it faster than protein language models can even generate sequence embeddings, by completely discarding traditional pair representations in favor of an inner-product-based, linear-memory "Flashpoint Attention" (FPA) algorithm.
Featuring roughly 7.2 million parameters trained on 8,395 SAbDab structures, the model is strictly forced to run on float32 precision to avoid the catastrophic numerical cancellation errors that heavily degrade 16-bit float implementations during distance calculations.
Eliminating the structural compute bottleneck allows developers to scale downstream analysis to millions of sequences; using the variant tool FlashTAP, teams can filter out liability flags and predict therapeutic developability metrics for 100 antibodies per second.
Having said that, CDR-H3 is still sota - so in the region of 2.5A, but it gets there way faster.
Novel de novo protein binder design pipeline from Boltz that pairs an optimized candidate generation engine with BoltzPPI, a novel, interaction-aware scoring model built to rank designs based on binding confidence rather than just geometric plausibility.
To train BoltzPPI, the authors created a set of positive labels (PDB and patent complexes) and negative labels (synthetic non-interacting protein pairs co-localized via Boltz-2). This input pool (token, pair, distance, and mask features) is processed through a Pairformer stack using specific optimization tricks (co-trained focal loss, multi-view representation dropping, and Gaussian noise injection) to predict a binary binding-confidence score.
Significantly improves experimental VHH design performance, boosting the confirmed-binder hit rate from 3.3% to 8.0% on novel targets and successfully discovering screening hits for 7 out of 10 benchmark targets from the Chai-2 dataset.
Yields highly manufacturable binders, with 58% of its confirmed candidates passing a comprehensive panel of strict biophysical filters (such as thermal stability, purity, and low aggregation Propensity), outperforming both BoltzGen (40%) and clinical-stage VHH controls (21%).
Generates structurally distinct binders whose CDR loops remain highly distinct from any known entries in the SAbDab database, with the entire pipeline made available to researchers via the Boltz API and Lab platforms.